New Schedule Listings - Alliance Pharmaceuticals

In July 2021 API Consumer Brands announced its exit from the New Zealand pharmaceutical market, thus affecting the supply of a number of important products.

Max Health has since taken over the supply for the following API products.

Name: Buccastem (Prochlorperazine Maleate) tablets

Strength: 3mg x 50

Onelink Code: PHE274

Pharmacode: 340537

Price: POA

Buccastem tablets are listed in Section B of the Pharmaceutical Schedule.

Name: Syntometrine (Oxytocin and Ergometrine) Injection

Strength: 5IU/mL oxytocin 0.5mg/mL ergometrine in 5 x 1mL ampoules  

Onelink Code: 256269

Pharmacode: CSP012

Price: POA

Syntometrine injection is currently listed in both Section B and H of the Pharmaceutical Schedule and will enjoy sole supply in the latter from December 1, 2022.

These products will be supplied by our UK partner, Alliance. This partnership continues to exemplify the reliability and integrity of Alliance; Max Health looks forward to growing their portfolio in New Zealand.

The aforementioned products from Alliance are available now from OneLink, as is the rest of the extensive portfolio Max Health offers. These can be ordered from:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

New Tender Listing – An Addition to Hameln’s Portfolio

Hameln, once again, have proven their European products superior to many alternatives offered to the New Zealand market. Dexamethasone, supplied by Max Health’s German supplier Hameln, has been awarded in the recent tender announcement.

Being on the World Health Organisation’s List of Essential Medicines, Dexamethasone solution for injection, is relied on by a number of patients throughout the country and Max Health is proud to be able to supply a product of the highest quality to meet these needs. Manufactured in Europe in accordance with some of the highest regulatory standards in the world, Hameln’s Dexamethasone will be available in New Zealand from August 12th and will enjoy principal supply status until June 30 2025. Dexamethasone details follow.

 Name: Dexamethasone Phosphate Injection  

Strength: 4mg/mL, 1mL x 10

Onelink Code: PHAZ823

Pharmacode: 2451689

Price: POA

Name: Dexamethasone Phosphate Injection  

Strength: 4mg/mL, 2mL x 10

Onelink Code: PHAG90

Pharmacode: 2519143

Price: POA

Max Health products can be ordered from our distributor, Onelink via the following contact details.

Phone: 0800 70 80 60

Fax: 0800 26 69 60

Partner Update – A Focus on Hameln

Over the last 130 years Hameln has grown into an international supplier of generic pharmaceuticals, specialising in injectables. It boasts an impressive history, having been bought from the inventor of morphine, Friedrich Wilhelm Adam Sertϋrner. This foundation continues to influence the focus of Hameln’s growth and its expertise in manufacturing and distributing analgesics.

Whilst Hameln is based in Germany, it has a number of offices located around the world including in Hong Kong, the Netherlands, the UK, and Australia. Hameln products are manufactured in state-of-the-art facilities to a high quality, in accordance with New Zealand and European regulatory standards. Hameln has been a trusted supplier to Max Health for a number of years and continue to provide a service from which is rooted its core values of loyalty, openness, and reliability.  

Max Health is proud to be supplying Hameln products to the New Zealand market, three of which have recently been awarded in the tender. For two of these products, Cyclizine and Amiodarone Injections, the tender agreement ensures continual supply of the Hameln product already being used in the market. Both Cyclizine and Amiodarone will be listed in Sections H and B of the Pharmaceutical Schedule. The details for these products are as follows.

Name: Cyclizine Lactate Injection

Strength: 50mg/mL in 1mL x 10

Onelink Code: PHAS85

Pharmacode: 2595877

Price: POA

Name: Amiodarone Hydrochloride Injection  

Strength: 50mg/mL in 3mL x 10

Onelink Code: PHAN24

Pharmacode: 2565129

Price: POA

Both Cyclizine and Amiodarone Injections will continue to enjoy principal supply status until June 30th, 2025.

Another Hameln product, Naloxone, is authorised for Denmark, Germany, Sweden, the UK and the Netherlands and is now available to the New Zealand market. Naloxone Injection will enjoy sole supply until June 30th, 2024. This will be listed in Sections H and B of the Pharmaceutical Schedule. The change in subsidy will occur on September 1st, 2022. Details for Naloxone is as follows.

Name: Naloxone Hydrochloride Injection  

Strength: 400mcg/mL in 1mL x 10

Onelink Code: PHAZ58

Pharmacode: 2634090

Price: POA

All Max Health products, including those supplied by Hameln as well as other industry-leading pharmaceuticals, are distributed by Onelink. These can be ordered from:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Orion Pharma and Max Health Partnership in NZ

Good afternoon,

Max Health is pleased to announce the following news regarding its partner Orion.

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Company website: https://www.orion.fi/en/

Since 2020 Orion has expanded its commercial footprint to the Asia Pacific region (Malaysia, Singapore and Thailand). This year the company is establishing its own operations in New Zealand and Australia.

Max Health™ was established in 2008 and distributes a variety of pharmaceutical and medical products in New Zealand for a number of international partners. Their expertise, local knowledge and network of contacts has helped build a solid reputation for reliability and innovation in the NZ pharmaceutical sector. They have distributed a number of Orion products in NZ since their first Orion  launch in 2012.

Orion has plans to invest in NZ and to offer an expanded range of products to NZ patients. While Orion has committed to establishing a NZ subsidiary, it is important to note that they have retained the services of Max Health to its represent its products to NZ customers, and to bring its products under one umbrella in this country. Max Health is delighted to be partnering with Orion in this exciting expansion of their product portfolio in NZ.

If you have any questions please feel free to contact me.

Best regards,

Patrick Forrester

Director- Max Health Ltd

Mob: 021 311 357  Ph: +64 9 815 2664

Octreotide Injection - New Tender Listing - Section B and Section H

Max Health is pleased to confirm that is has been awarded the tender for all three strengths of Octreotide Injection – 50mcg/mL in 1mL; 100mcg/mL in 1mL; 500mcg/mL in 1mL. These are supplied by our Australian partner, Generic Health. Octreotide Injections will be listed in both sections H and B of the Pharmaceutical Schedule and will have Principal Supply Status until 30 June 2024.

This change in subsidy will occur on February 1st 2022.

Distribution of all Max Health products, including Octreotide Injections, are managed by Onelink. These can be ordered from:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Octreotide Injection details are as follows:

Name: Octreotide Injection

Strength: 50mcg/mL in 1mL x 5

Onelink Code: PHAX70

Price: POA

Name: Octreotide Injection

Strength: 100mcg/mL in 1mL x 5

Onelink Code: PHAX71

Price: POA

Name: Octreotide Injection

Strength: 500mcg/mL in 1mL x 5

Onelink Code: PHAX72

Price: POA

Oxycodone Injection – New Tender Listing – Section B And Section H

Max Health is happy to announce that is has been awarded the tender for all three presentations of Oxycodone Injection - 10mg/mL in 1mL; 10mg/mL in 2mL; 50mg/mL in 1mL. These are manufactured by our German supplier, Hameln. Oxycodone Injections will be listed in both sections H and B of the Pharmaceutical Schedule and will enjoy Principal Supply Status until 30 June 2024.

This change in subsidy will occur on February 1st 2022.

Distribution of the Oxycodone Injections range, as well as all other Max Health products, are handled by Onelink. These can be ordered from Onelink on:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Oxycodone Injection details are as follows:

Name: Oxycodone Injection

Strength: 10mg/mL in 1mL x 5

Onelink Code: PHAZ07

Price: POA

Name: Oxycodone Injection

Strength: 10mg/mL in 2mL x 5

Onelink Code: PHAZ08

Price: POA

Name: Oxycodone Injection

Strength: 50mg/mL in 1mL x 5

Onelink Code: PHAZ09

Price: POA

Neostigmine Metisulfate Injection – New Tender Listing – Section B and Section H

Max Health is happy to report that is has been awarded the tender for Neostigmine Metisulfate injection 2.5mg/mL in 1mL. This product is manufactured by our German supplier, Hameln. Neostigmine Metisulfate will be listed in both sections H and B of the Pharmaceutical Schedule, and will enjoy Principal Supply Status until 30 June 2024.

This change in subsidy will occur on October 1st 2021.

Distribution of all Max Health products, including Neostigmine Metisulfate, will be handled by Onelink. These can be ordered from Onelink on:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Neostigmine Metisulfate Injection details are as follows:

Name: Neostigmine Metisulfate Injection

Strength: 2.5mg/mL, 1mL amps x 10

Onelink Code: PHAT58

Pharmacode: 2599996

Price: POA

Flumazenil Injection – New Tender Listing – Section H

Max Health is pleased to announce that it has been awarded the tender for Flumazenil Injection 0.1mg/mL in 5mL. This product is manufactured by our long-standing German supplier, Hameln. Flumazenil will be listed in Section H of the Schedule.

This change in subsidy will occur on September 1st, 2021.

Distribution of Flumazenil Injection will be handled by Onelink along with all other Max Health products. These can be ordered from Onelink on:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Flumazenil Injection details are as follows:

Name: Flumazenil Injection

Strength: 0.1mg/mL, 5mL amps x 10

OneLink Code: PHAL99

Pharmacode: 2558904

Price: POA

Dopamine Hydrochloride Injection – New Tender Listing – Section H

Max Health is happy to announce that it has been awarded the tender for Dopamine Hydrochloride 200mg/5mL. This injection is manufactured by Martindale. Dopamine will be listed in Section H of the Schedule.

This change in subsidy will occur on November 1st, 2021.

Distribution of Dopamine Hydrochloride Injection will be handled by Onelink, as are all Max Health products. All Max Health products can be ordered from Onelink on:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Dopamine Hydrochloride Injection details are as follows:

Name: Dopamine Hydrochloride

Strength: 40mg/mL, 5mL x 10

OneLink Code: PHY722

Pharmacode: 2374374

Price: POA

Atropine Sulphate Injection – New Tender Listing – Section H and Section B

Max Health is pleased to announce that it has been awarded the tender for Atropine Sulphate 600mcg/mL. This product is manufactured by Martindale, based out of the UK. Atropine Sulphate will be listed in Section H and Section B of the Schedule.

Max Health will commence with this change in subsidy on August 1 2021.

Distribution of Atropine Sulphate will be handled by Onelink, as are all other Max Health products. Max Health products can be ordered from Onelink on:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Atropine Sulphate injection details are as follows:

Name: Atropine Sulphate

Strength: 600mcg/1 mL

Onelink Code: PHAI22

Pharmacode: 2528754

Price: POA

Max Health Announces NZ Registration of Lynley™ (Ethinylestradiol 30mcg and Levonorgestrel 150mcg) Oral Contraceptive pill

Max Health is pleased to announce that it has received approval from Medsafe for the registration of Ethinylestradiol 30mcg and Levonorgestrel 150mcg (branded as Lynley™) oral contraceptive for use in New Zealand. This registration is effective from 11 March 2021.

This product is part of a collaboration with our Australian partner, Generic Health, and is manufactured by leading international generic pharmaceutical company, Lupin. We await a decision from PHARMAC regarding potential reimbursement of the product.

Dobutamine Injection – New Tender Listing – Section H

Max Health is excited to announce that it has been awarded the tender for Dobutamine 12.5mg/mL. This product is manufactured in Germany by its trusted partner, Hameln. Dobutamine will be listed in Section H of the Schedule.

 Distribution of Dobutamine, as well as all other Max Health products, continues to be handled by Onelink. Max Health products can be ordered from Onelink on:

Phone: 0800 70 80 60

Fax: 0800 26 69 60

E-mail: customerservices@onelink.co.nz

Dobutamine injection details are as follows:

Name: Dobutamine 

Strength: 12.5 mg/1 mL

Onelink Code: PHZ805

Pharmacode: 1123349

Price: POA